Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
MOMA Therapeutics
Eli Lilly and Company
Kivu Bioscience Inc.
M.D. Anderson Cancer Center
AstraZeneca
Mersana Therapeutics
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
Nammi Therapeutics Inc
Regor Pharmaceuticals Inc.
Exscientia AI Limited
Fate Therapeutics
Conjupro Biotherapeutics, Inc.
National Institutes of Health Clinical Center (CC)
Conjupro Biotherapeutics, Inc.
Arcus Biosciences, Inc.
Sotio Biotech Inc.
EMD Serono
Eli Lilly and Company
National Cancer Institute (NCI)
SystImmune Inc.
M.D. Anderson Cancer Center
Institut Paoli-Calmettes
Atavistik Bio, Inc
NiKang Therapeutics, Inc.
Alterome Therapeutics, Inc.
BeOne Medicines
ViroMissile, Inc.
Accent Therapeutics
Tizona Therapeutics, Inc
Clasp Therapeutics, Inc.
Normunity AccelCo, Inc.
NiKang Therapeutics, Inc.
Poseida Therapeutics, Inc.
IDEAYA Biosciences
MacroGenics
Avacta Life Sciences Ltd
SystImmune Inc.
SN BioScience
M.D. Anderson Cancer Center
Eli Lilly and Company
Shanghai Best-Link Bioscience, LLC
University of Washington
Seagen Inc.
Fusion Pharmaceuticals Inc.
Innate Pharma
Dren Bio
Novartis
M.D. Anderson Cancer Center